問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

施宣任SHIH, HSUAN JEN
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

57Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

施宣任

List

73Cases

2021-04-01 - 2026-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Not yet recruiting17Sites

2021-08-01 - 2023-03-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-09-01 - 2028-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Suspended1Sites

2022-04-01 - 2029-10-31

Phase III

A Randomized, 2-Arm, Phase 3 Study of Elranatamab (PF-06863135) Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    Elranatamab Lenalidomide

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2020-11-01 - 2026-12-31

Phase III

Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Subjects ≤65 Years With Previously Untreated Non-Germinal Center DLBCL

  • Condition/Disease

    non-germinal center diffuse large B-cell lymphoma

  • Test Drug

    ACP-196

Participate Sites
7Sites

Recruiting7Sites

2021-11-01 - 2030-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-12-25 - 2025-07-31

Phase III

A randomized, double-blind, placebo-controlled, active-comparator, multicenter, phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

  • Condition/Disease

    diffuse large B-cell lymphoma (DLBCL)

  • Test Drug

    Brentuximab Vedotin, Lenalidomide,Rituximab

Participate Sites
7Sites

Recruiting7Sites

2021-03-17 - 2025-06-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-07-30 - 2025-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-05-10 - 2022-09-26

Phase II

A Phase 1/2 Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 701 Monotherapy, or in Combination with Pomalidomide with and without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B)

  • Condition/Disease

    Relapsed/Refractory Multiple Myeloma

  • Test Drug

    AMG701

Participate Sites
3Sites

Terminated3Sites

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB